Nuvilex Makes First Appearance at BIO International Convention

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announced today it is attending the 2011 BIO International Convention in Washington, D.C. This major international gathering of biotechnology entities, sponsored by the Biotechnology Industry Organization (BIO), occurs at the Walter E. Washington Convention Center from June 27-30.

The Convention is a global event with over 15,000 attendees from 48 states and 60 countries expected. Major pharmaceutical companies such as Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Merck, and many others will be present at the event as will major research and clinical institutions and government regulatory agencies such as the FDA. The annual BIO Convention is a widely-publicized event in the media. At the 2010 convention, 337 media outlets representing 23 countries were present; these generated more than 1,300 stories and over 1.5 billion impressions.

At the Convention, Nuvilex will be joining SG Austria, recently acquired by Nuvilex, in the Singapore Pavilion and will be available to discuss the Nuvilex – SG Austria connection with interested individuals. We will be working with international and domestic companies with whom SG Austria already has had contact to initiate and/or finalize possible cooperative agreements and to create and develop new ones. Nuvilex will also be promoting its live-cell encapsulation technology and emphasizing its remarkable potential to individuals, company representatives, researchers, and clinicians with the aim of establishing future opportunities and monetizing the technology. In addition, we plan to hold meetings with various sources of funding while at the Convention.

This initial appearance by Nuvilex at the major International Biotechnology Convention of 2011 will serve to establish the Company’s presence in the biotechnology sector and to increase the visibility and value of live-cell encapsulation.

Nuvilex is:

an innovative biotechnology and natural products company. Please come visit us in the Singapore Pavilion. Recent acquisitions include a treatment for advanced pancreatic cancer and SG Austria, the world’s leading live-cell encapsulation company. The pancreatic cancer treatment is being readied for additional clinical trials and significant advances are in progress with the live-cell-encapsulation technology. Current natural products include Gluten-Free Cinnergen™, Cinnechol™, and Cinnsational™ to enhance a healthy lifestyle; Talsyn™ and NumaDerm™ for cosmetic use; Reme-Flu™, Legacy Biotechnologies’ flu combating regimen; Virgin® and Infinitink®, heavy-metal-free tattoo inks; and additional developments are planned for Citroxin™ and Oraphyte™, Nuvilex’s antimicrobial and antinematodal agents, respectively.

Safe Harbor Statement

This information may contain forward-looking statements involving risks and uncertainties. Results, events and performances could vary from those contemplated. These risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes including product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making investment decisions. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro
702-434-8692
IR email: [email protected]

KEYWORDS:   United States  North America  Arizona  District of Columbia

INDUSTRY KEYWORDS:   Health  Biotechnology  Fitness & Nutrition  Genetics

MEDIA:

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.